- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07942142
A Registry Evaluating the Real-World Clinical Use, Procedural Characteristics, Safety, and Effectiveness of the VARIPULSE™ PRO Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation
Real-World Outcomes and Procedural Practice Patterns of VARIPULSE™ PRO Ablation for Atrial Fibrillation
The purpose of this study is to learn more about how safe and how well a treatment called catheter ablation works to treat atrial fibrillation (AF) when the VARIPULSE system is used.
This study collects information from people receiving this treatment as part of their usual medical care. Researchers want to understand how the procedure is used in everyday practice.
The secondary purpose of this study is to create a registry to collect data to be used for future research.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Carla Girolametto
- 전화번호: 5194974300
- 이메일: carla.girolametto@wrhn.ca
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients undergoing catheter ablation for atrial fibrillation using the VARIPULSE PRO platform.
설명
Inclusion Criteria:
- Symptomatic paroxysmal atrial fibrillation (AF episode that terminates spontaneously within 7 days)
- Indicated for catheter ablation in the opinion of the investigator
- De Novo and redo AF ablation procedures
- Age > 18 years
- Will be treated with Biosense Webster Inc. Ablation Technologies
- All AF ablations performed with BWI technology.
- Able and willing to participate in baseline and follow-up evaluations.
Exclusion Criteria:
- Age <18 years
- Persistent atrial fibrillation
- Non-AF ablation procedures without AF treatment
- Inability to provide informed consent
- Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
- In the opinion of the investigator, any known contraindication to an ablation procedure
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: OTHER
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Procedural Characteristics and Lesion Delivery Patterns of VARIPULSE™-Based Atrial Fibrillation Ablation Using the PRO Sequence
기간: During the index ablation procedure.
|
To characterize real-world procedural practices associated with VARIPULSE™ pulsed field ablation using the PRO sequence in patients undergoing atrial fibrillation ablation. Measures will include total number of PFA applications, number of applications delivered per pulmonary vein, lesion distribution within the left atrium, completeness of pulmonary vein lesion sets, and use of adjunctive ablation strategies. Additional lesion sets, including posterior wall isolation, roof line, mitral isthmus, cavotricuspid isthmus, anterior wall and other mapped atrial tachycardia targets, will also be documented. |
During the index ablation procedure.
|
|
Procedural Workflow and Efficiency Metrics
기간: During the index ablation procedure.
|
To evaluate procedural workflow, duration and resource utilization during VARIPULSE™-based atrial fibrillation ablation. Measures will include total procedure duration, left atrial dwell time, fluoroscopy time, radiation dose, number of transseptal punctures, total ablation time, and use of adjunctive ablation technologies, including supplemental radiofrequency ablation. Additional procedural characteristics will include anesthesia type, ventilation strategy, intracardiac echocardiography utilization, electroanatomical mapping workflow and left atrial voltage map acquisition. |
During the index ablation procedure.
|
|
Pulmonary Vein Lesion Delivery and Isolation Characteristics
기간: During the index ablation procedure.
|
To characterize pulmonary vein lesion delivery and isolation efficiency during VARIPULSE™ PFA procedures using the PRO sequence. Measures will include total lesions delivered, number of lesions per pulmonary vein, completeness of concentric lesion rings, number of lesions required to achieve pulmonary vein isolation, and pulmonary vein isolation transpired time. Pulmonary vein isolation transpired time is defined as the interval between the first and final pulmonary vein ablation applications, excluding subsequent touch-up lesions performed following additional linear lesion sets. |
During the index ablation procedure.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .